TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma
Cellular Oncology · 2024
DOI: 10.1007/s13402-024-01014-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Xuejie Min und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Early Growth Response Protein 1, Ribosomal Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Research Foundation of State Key Laboratory of Systems Medicine.
Abstract (Originalsprache)
PURPOSE: Terminal nucleotidyltransferase 5A (TENT5A), recently predicted as a non-canonical poly(A) polymerase, is critically involved in several human disorders including retinitis pigmentosa, cancer and obesity. However, the exact biological role of TENT5A in hepatocellular carcinoma (HCC) has not been elucidated. METHODS: The transcription level of TENT5A and clinical correlation were analyzed using the LIRI-JP cohort, the TCGA-LIHC cohort, and clinical tissue samples of HCC patients in our laboratory. Proliferation, migration, and invasion were detected with stably TENT5A overexpressing and knockdown HCC cells in vitro and in vivo. Chromatin immunoprecipitation and dual-luciferase reporter assay were performed to verify the binding of the target protein to DNA. Co-immunoprecipitation and GST pull-down assay combined with mass spectrometry (MS) were used to identify protein interactions. RESULTS: Our study presented here shows that TENT5A is downregulated in HCC tissues, suggesting a shorter overall survival for patients. Gain- and loss-of-function experiments reveal that TENT5A suppresses the proliferation and metastasis, and the residue Gly122 is of great importance to the role of TENT5A in HCC. More importantly, EGR1 (Early growth response 1) directly binds to the TENT5A promoter and promotes TENT5A expression. By interacting with RPL35, TENT5A is involved in ribosome biogenesis and exerts a negative regulatory effect on the mTOR pathway. CONCLUSIONS: Our findings illustrate the role of the oncosuppressive function of TENT5A in HCC and suggest that the EGR1/TENT5A/RPL35 regulatory axis may be a promising target for therapeutic strategies in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China.
- Department of Pathology, Qi Dong Liver Cancer Institute, Qidong, 226220, China.
- Department of Animal Experimental Center, Fudan University Shanghai Cancer Center, Shanghai, 201102, China.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China. jjli@shsci.org.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai, 200032, China. hongli@shsci.org.
Förderung
- National Natural Science Foundation of China
- Research Foundation of State Key Laboratory of Systems Medicine
Zitieren
APA
Min, X., Lin, F., Zhao, X., Yu, J., Ge, C., Zhang, S., Li, X., Zhao, F., Chen, T., Tian, H., Yan, M., Li, J., & Li, H. (2024). TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma. Cellular Oncology. https://doi.org/10.1007/s13402-024-01014-9
Vancouver
Min X, Lin F, Zhao X, Yu J, Ge C, Zhang S, et al. TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma. Cellular Oncology. 2024. doi:10.1007/s13402-024-01014-9
BibTeX
@article{Min2024,
author = {Min, Xuejie and Lin, Fen and Zhao, Xinge and Yu, Junming and Ge, Chao and Zhang, Saihua and Li, Xianxian and Zhao, Fangyu and Chen, Taoyang and Tian, Hua and Yan, Mingxia and Li, Jinjun and Li, Hong},
title = {TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma},
journal = {Cellular Oncology},
year = {2024},
doi = {10.1007/s13402-024-01014-9}
}
EUVIMED